Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Adamakis

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Pharmacogenomics|November 15, 2012
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group studyNikitas Nikitas, Alexandra Karadimou, Eliza Tsitoura, et al.
Anti-Cancer Drugs|October 1, 2015
Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer GroupNikolaos Pistamaltzian, Kimon Tzannis, Vassiliki Pissanidou, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer GroupAristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, et al.
World Journal of Urology|July 11, 2016
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patientsMichalis Liontos, Eleni-Andriana Trigka, Penelope Korkolopoulou, et al.
Clinical Genitourinary Cancer|February 3, 2020
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line ChemotherapyAristotelis Bamias, Kimon Tzannis, Ioannis Dimitriadis, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational StudyAristotelis Bamias, Kimon Tzannis, Roubini Zakopoulou, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Pharmacogenomics|November 15, 2012
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group studyNikitas Nikitas, Alexandra Karadimou, Eliza Tsitoura, et al.
Anti-Cancer Drugs|October 1, 2015
Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer GroupNikolaos Pistamaltzian, Kimon Tzannis, Vassiliki Pissanidou, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer GroupAristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, et al.
World Journal of Urology|July 11, 2016
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patientsMichalis Liontos, Eleni-Andriana Trigka, Penelope Korkolopoulou, et al.
Clinical Genitourinary Cancer|February 3, 2020
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line ChemotherapyAristotelis Bamias, Kimon Tzannis, Ioannis Dimitriadis, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational StudyAristotelis Bamias, Kimon Tzannis, Roubini Zakopoulou, et al.
Pageof 4